Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A sensitive and specific analytical method for cannabidiol (CBD) in urine was needed to define urinary CBD pharmacokinetics after controlled CBD administration, and to confirm compliance with CBD medications including Sativex—a cannabis plant extract containing 1:1 ∆9-tetrahydrocannabinol (THC) and CBD. Non-psychoactive CBD has a wide range of therapeutic applications and may also influence psychotropic smoked cannabis effects. Few methods exist for the quantification of CBD excretion in urine, and no data are available for phase II metabolism of CBD to CBD-glucuronide or CBD-sulfate. We optimized the hydrolysis of CBD-glucuronide and/or -sulfate, and developed and validated a GC-MS method for urinary CBD quantification. Solid-phase extraction isolated and concentrated analytes prior to GC-MS. Method validation included overnight hydrolysis (16 h) at 37 °C with 2,500 units β-glucuronidase from Red Abalone. Calibration curves were fit by linear least squares regression with 1/x2 weighting with linear ranges (r2 > 0.990) of 2.5–100 ng/mL for non-hydrolyzed CBD and 2.5–500 ng/mL for enzyme-hydrolyzed CBD. Bias was 88.7–105.3 %, imprecision 1.4–6.4 % CV and extraction efficiency 82.5–92.7 % (no hydrolysis) and 34.3–47.0 % (enzyme hydrolysis). Enzyme-hydrolyzed urine specimens exhibited more than a 250-fold CBD concentration increase compared to alkaline and non-hydrolyzed specimens. This method can be applied for urinary CBD quantification and further pharmacokinetics characterization following controlled CBD administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Self-citationAction of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1×
“Cannabidiol (CBD) is proposed as oral or oromucosal pharmacotherapy for diverse conditions including dementias, cerebral ischemia, diabetes, inflammatory diseases, nausea, and psychiatric disorders [1–3] over a wide dosage range [4].”
BackgroundCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.318 · Cited by 117 · cited 1×
“In our previous Sativex studies, which evaluated cannabis plant extracts rich in CBD and THC, we did not find any significant interaction with THC’s physiological or psychotropic effects [12, 13].”
BackgroundSelf-citationZuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2495-x · Cited by 84 · cited 1×
“It has been suggested that CBD can modulate THC’s physiological and psychological effects in humans [10], although CBD/THC ratio may be an important factor [11].”
Background
Cited by
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., Sweeney, J. M., Miyauchi, J. T., Tsirka, S. E., Ojima, I., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.618447 · Cited by 312
Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 298
A Conversion of oral cannabidiol to delta9-tetrahydrocannabinol seems not to occur in humans
Nahler, G., Grotenhermen, F., Zuardi, A. W., & Crippa, J. A. S. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2017.0009 · Cited by 61
Nuapia, Y., Tutu, H., Chimuka, L., & Cukrowska, E. (2020) · Molecules · doi:10.3390/molecules25061335 · Cited by 50
Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal.
Kevin, R. C., Allsop, D. J., Lintzeris, N., Dunlop, A. J., Booth, J., & McGregor, I. S. (2017) · Forensic Toxicology · doi:10.1007/s11419-016-0330-0 · Cited by 24
Metadata
- Authors
- Bergamaschi, M. M., Barnes, A., Queiroz, R. H. C., Hurd, Y. L., & Huestis, M. A.
- Venue
- Analytical and Bioanalytical Chemistry
- Published
- 2013-03-15
- Volume
- 405
- Issue
- 14
- Pages
- 4679-4689
- ISSN
- 1618-2642 (ISSN-L)
- 1618-2650
- OpenAlex
- W2031773337
- Cited by
- 43
- References
- 7
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. https://app.cochat.ai/papers/10.1007/s00216-013-6837-x
- The paper
- Bergamaschi, M. M., Barnes, A., Queiroz, R. H. C., Hurd, Y. L., & Huestis, M. A. (2013). Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Analytical and Bioanalytical Chemistry. https://doi.org/10.1007/s00216-013-6837-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.